http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
-
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
-
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
-
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
-
Exact Sciences (EXAS): New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
-
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
-
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
-
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
-
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
-
Exact Sciences (EXAS) Unveils Data Showing Promise of Multi-Cancer Early Detection
-
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
-
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
-
Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test
-
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
-
Exact Sciences (EXAS) Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
-
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
-
Exact Sciences to Participate in September Investor Conferences
-
Exact Sciences (EXAS) Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
-
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
-
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
-
Exact Sciences (EXAS) and TwinStrand Biosciences Enter Exclusive License Agreement for Duplex Sequencing Technology
-
TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology
-
Exact Sciences Announces Second-Quarter 2024 Results
-
Exact Sciences schedules second quarter 2024 earnings call
-
Exact Sciences to Participate in June Investor Conferences
-
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
-
Exact Sciences Earns 2024 Great Place To Work® Certification™
-
Exact Sciences (EXAS) Reports Court Rules the Company to Proceed with Lawsuit against Geneoscopy
-
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
-
Exact Sciences Announces First-Quarter 2024 Results
-
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
-
Exact Sciences to Participate in May Investor Conference
-
Exact Sciences (EXAS) Appoints Aaron Bloomer as CFO
-
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
-
Exact Sciences (EXAS) Announces Debt Exchange Transaction, Private Convertible Notes Placement
-
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
-
Exact Sciences (EXAS) to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR
-
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
-
Exact Sciences Schedules First Quarter 2024 Earnings Call
-
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
-
Exact Sciences (EXAS) Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
-
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
-
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
-
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
-
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
-
Exact Sciences to Participate in March Investor Conference
-
Exact Sciences Announces Fourth Quarter 2023 Results
-
Exact Sciences Schedules Fourth Quarter 2023 Earnings Call
-
Exact Sciences (EXAS) Reports Prelim Q4 Results
-
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

